Lupin gets USFDA nod for generic version of Tamiflu capsules
New Delhi: Drug major Lupin on Wednesday said it has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Tamiflu capsules, used in treating influenza.
The company has received final approval from the US drug regulator to market oseltamivir phosphate capsules, a generic version of Hoffman-La Roche Inc.’s Tamiflu capsules in strengths of 30 mg, 45 mg, and 75 mg, Lupin said in a statement.
Oseltamivir phosphate capsules are used for the treatment of influenza. As per IMS MAT October 2017 data, the capsules clocked annual sales of around $467.8 million in the US market.
Shares of Lupin closed 0.46% up at Rs925.05 on the BSE.
- Indian scientists using artificial intelligence to predict early onset of Alzheimer’s
- People need to make preventive measure a habit if India is to become malaria-free by 2027: home insecticides makers
- Bollywood is in love with biopics. But will it last?
- Flipkart wins relief over tax on discounts
- Why homebuyers can’t expect any RERA relief soon